Figure 2
From: An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
Effect of predicted binding-site residue mutations on CT(a) or AMY1(a) receptor function. (a–c) The effect of mutation on hCT-mediated responses at either the CT(a) (a, left-hand panel; b) or AMY1(a) (a, right-hand panel; c) receptor. (d–f) The effect of mutation on rAmy (rat amylin) -mediated responses at either the CT(a) (d, left-hand panel; e) or AMY1(a) (d, right-hand panel; f) receptor. Homology models of the isolated CTR (blue) (b, e) or the CTR/RAMP1 complex (c, f) (CTR, blue; RAMP1, pink). Mutated residues are displayed in x-stick and CPK and coloured according to the magnitude of effect of mutation on peptide function (red, >50-fold decreased potency; orange, 10–50-fold decreased potency; yellow, <10-fold decreased potency; and blue, not significantly different). Data points are mean±s.e.m., combined from four to six independent experiments, performed in duplicate or triplicate; and displayed as change in potency of the peptide (pEC50).
